Effect of Combination Therapy of Methotrexate with Vitamin A in Patients with Low Risk GTN (Gestational Trophoblastic Neoplasia)

  title={Effect of Combination Therapy of Methotrexate with Vitamin A in Patients with Low Risk GTN (Gestational Trophoblastic Neoplasia)},
  author={Sedigheh Ghasemian and Z Karkhaneh Yousefi and Marjaneh Farazestanian and Leila Mousavi Seresht and Mohsen Foroughipour and Saeid Akhlaghi},
  journal={Iranian Journal of Pharmaceutical Research : IJPR},
  pages={38 - 42}
Methotrexate as a single agent chemotherapy in most women with low risk gestational trophoblastic neoplasia (GTN) has been associated with high treatment rate. Combination of methotrexate with Vitamin A due to reduced number of chemotherapy regime courses is one of the treatment options for patients with low-risk GTN. Therefore, this study was performed with aim to determine the efficacy of combination therapy of Methotrexate with Vitamin A in low risk GTN treatment. This randomized clinical… Expand
Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients
Oral administration of 6,000 IU vitamin A could help to reduce β-hCG levels in low-risk GTN patients who receive MTX chemotherapy, and the incidence of chemo resistance in the intervention group were lower than those in the control group. Expand
Evaluation of the Relation between Treatment Results and Predictive Factors in Metastatic and High Risk Gestational Trophoblastic Neoplasia
The World Health Organization/International Federation of Gynecology and Obstetrics staging-scoring system is appropriate for gestational trophoblastic neoplasia management and the etoposide, methotrexate, actinomycin D, cyclophosphamide, and oncovin regimen showed superior efficacy. Expand
Evaluation of High-Dose Vitamin A Treatment in Postmolar Patients with Low and Plateauing Serum Human Chorionic Gonadotropin Levels.
The limited use of HD Vit-A seems to have a safe and significant effect on the treatment of postmolar patients with low and plateauing serum human chorionic gonadotropin (hCG) levels and may decrease the development ofPostmolar GTN in this population. Expand
Effect of Different Doses of Vitamin A on β-HCG Production in Patients Suffering from Gestational Trophoblastic Disease
This study aimed to evaluate the effect of vitamin A doses (100,000 IU and 200,000IU) on the decrement of β-HCG levels in Gestational trophoblastic disease patients. Expand


Effect of Methotrexate Combination with Vitamin A on Serum Levels of beta hCG in Low Risk of Gestational Trophoblastic Tumors Treatment
Combination of vitamin A 100,000 IU and methotrexate can accelerate beta hCG serum declination in treatment of patients with low risk gestational trophoblastic neoplasia. Expand
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.
  • R. Osborne, V. Filiaci, +7 authors J. Lage
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
The biweekly dactinomycin regimen has a higher CR rate than the weekly IM methotrexate regimen in low-risk GTN, a generally curable disease. Expand
A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease.
The overall published results using weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease indicate that it is comparable in efficacy to other first-line treatments while having the advantages of convenience, low cost, and low toxicity. Expand
First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Moderate-certainty evidence indicates that actinomycin D is probably more likely to achieve a primary cure in women with low-risk GTN than methotrexate, and first-line met Hotrexate treatment is probablyMore likely to fail than actincycin D treatment, while evidence from subgroup analyses suggests that actInomycinD may be associated with a greater risk of SAEs than metHotrexate. Expand
Prevention of post-mole malignant trophoblastic disease with vitamin A.
The rate of malignant trophoblastic disease (MTD) was reduced in the group receiving vitamin A therapy, and no difference was found in the changes of SGOT and SGPT levels of the therapy group compared with the control group. Expand
The Use of Retinoids in Ovarian Cancer: A Review of the Literature
Preclinical studies and clinical trials conducted using retinoids in ovarian cancer, a class of compounds composed of vitamin A, its natural derivatives, and synthetic analogs, are reviewed. Expand
Study on retinol binding protein (RBP) receptor in hydatidiform mole trophoblastic cells
This study aimed to demonstrate the presence of retinol binding protein (RBP) receptors in the hydatidiform mole trophoblastic cells, that would provide explanation on the relationship of vitamin A and hydatodiform mole. Expand
Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole.
  • J. Lurain
  • Medicine
  • American journal of obstetrics and gynecology
  • 2010
Particular emphasis is given to management of hydatidiform mole, including evacuation, twin mole/normal fetus pregnancy, prophylactic chemotherapy, and follow-up. Expand
The Role of Antioxidants and Vitamin A in Ovarian Cancer: Results From the Women's Health Initiative
The results from this prospective study of well-nourished, postmenopausal women suggest that intake of dietary antioxidants, carotenoids, and vitamin A are not associated with a reduction in ovarian cancer risk. Expand
Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN)
An RAR-independent mechanism in which CD437 causes DNA adduct-formation is suggested, resulting in induction of a p53-independent DNA damage response, and subsequent growth-arrest and apoptosis, may also explain its apoptotic effects in other cell types. Expand